Monoclonal Antibody Research in Pancreatic Cancer

Monoclonal Antibody Research in Pancreatic Cancer

Monoclonal Antibody Research in Pancreatic Cancer

Monoclonal antibodies (mAbs) are an attractive therapeutic option for the treatment of patients with a wide range of cancers, including pancreatic cancer (PC). Currently, multiple target antigens exist in PC and the therapeutic and diagnostic potential of mAbs for PC has been investigated. To advance the development of mAb-based drugs against PC, Alfa Cytology provides research services for mAbs, including in vitro pharmacology, in vivo pharmacology and in vivo safety assessment.

Our infrastructure and expertise

Alfa Cytology is a leading global life sciences company. We have years of experience in constructing models for PC, including PC cell models, PC organoids, genetically engineered mouse models, and transplantation models. Each model has its own characteristics and applications.

  • PC cell model

Newly established PC cell lines may provide sufficient models for studying the broader biological and molecular features of PC. We are now offering in vitro models of PC, including 2D cell lines and 3D spheroids.

  • PC organoid model

Organoids allow not only the study of tissue function but also co-culture, which serves as an important tool for PC research. Based on our advanced platforms and experienced scientists, we can establish customized, cost-effective, and stable PC organoids to meet the specific requirements of our global customers.

  • Genetically engineered mouse model of PC

Genetically engineered mouse models not only inspire the biology of PC and highlight the importance of tumor stroma, but also have the ability to elucidate potential therapeutic and diagnostic targets. To meet experimental requirements in terms of quantity and quality, we have launched a systematic animal model transgenic platform for PC research.

  • Transplantation model of PC

Several xenograft models of PC are available at Alfa Cytology, including cell line-derived xenografts (CDXs), spheroid-based xenografts (SDXs), organoid-derived xenografts (ODXs),and patient-derived xenografts (PDXs).

Monoclonal Antibody Research in Pancreatic Cancer

The service offering at Alfa Cytology

  • In vitro pharmacology

-Cell proliferation assay

-Internalisation research

-Neutralization assay

-Customized functional assay cell line construction

-Immune cell stimulation and multiple cytokine release assay

-Antibody-dependent cellular cytotoxicity assay

-Cellular characterization assay by flow cytometry

  • In vivo pharmacology

In vivo efficacy is the gold standard for evaluating the biological activity of antibody drugs and is the first comprehensive activity validation prior to clinical studies. In vivo efficacy evaluation is an essential step in the antibody-drug development process and plays a critical role in the screening of antibody-drug candidates and clinical target indications. We offer the following services, including:

-In vivo efficacy study in PC cell line xenograft model

-In vivo efficacy study in patient-derived xenograft model

  • In vivo safety assessment

-Single-dose toxicology

-Repeat-dose toxicology

-Topical toxicity study

-Developmental and reproductive toxicology

Benefits of our services

  • Well-established PC models
  • The excellent project management team
  • One-stop efficient service, customizing the steps from in vitro to in vivo
  • Specialized capabilities and extensive resources in mAb-based drug development and complex PC biology

We have developed a series of in vitro and in vivo bioassays based on cellular and animal models to ensure a smooth workflow and to obtain the best antibody leads. Our extensive knowledge of mAb-based drug development and complex PC biology allows us to help our clients achieve optimal study design and rapid research start-ups. If you are interested in our services, please contact us for more details. We look forward to working with you on your next project.


  1. Arias-Pinilla, Gustavo A., and Helmout Modjtahedi. "Therapeutic application of monoclonal antibodies in pancreatic cancer: advances, challenges and future opportunities." Cancers 13.8 (2021): 1781.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.